Xlife Sciences AG (XSWX:XLS) Cyclically Adjusted PS Ratio: (As of Jul. 01, 2026)


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.55
GF Value CHF7.27
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Cyclically Adjusted PS Ratio?

Xlife Sciences AG does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xlife Sciences AG  (XSWX:XLS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Xlife Sciences AG Cyclically Adjusted PS Ratio Related Terms


Xlife Sciences AG Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Cyclically Adjusted PS Ratio Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSWX:XLS vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Xlife Sciences AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Cyclically Adjusted PS Ratio falls into.


XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Xlife Sciences AG does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.55 is trading 155.2% above its estimated GF Value™ of CHF7.27. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: CHF7.27 vs. price of CHF18.55 (155.2% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.55
Price
CHF7.27
GF Value